ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。2型糖尿病患者死于心血管疾病（CVD）的比率是具有相似人口统计学特征的非糖尿病人群的2 - 4倍。他们患非致命性心肌梗塞和中风的几率也会增加。随着美国肥胖症的日益流行，与2型糖尿病相关的心血管疾病预计将在未来几十年成为比现在更大的公共卫生挑战。预计事件发生率的增加将与随之而来的痛苦和资源利用的增加有关。尽管这一健康问题在北美人群中很重要，但关于强化控制血糖和其他心血管疾病危险因素对糖尿病患者心血管疾病发生率的影响，缺乏明确的数据。控制糖尿病心血管风险行动（ACCORD）试验的总体目标是通过测试2型糖尿病的三种互补药物治疗策略来解决这一挑战，以增加降低2型糖尿病中仍然很高的主要心血管疾病发病率和死亡率的选择。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates two to four times higher than non-diabetic populations of similar demographic characteristics. They also experience increased rates of nonfatal myocardial infarction and stroke. With the growing prevalence of obesity in the United States, CVD associated with type 2 diabetes is expected to become an even greater public health challenge in the coming decades than it is now. Expected increases in event rates will be associated with a concomitant rise in suffering and resource utilization. Despite the importance of this health problem in the North American population, there is a lack of definitive data on the effects of intensive control of glycemia and other CVD risk factors on CVD event rates in diabetic patients. The overall goal of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is to address this challenge by testing three complementary medical treatment strategies for type 2 diabetes to enhance the options for reducing the still very high rate of major CVD morbidity and mortality in this disease.